JP7668273B2 - Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 - Google Patents

Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 Download PDF

Info

Publication number
JP7668273B2
JP7668273B2 JP2022522065A JP2022522065A JP7668273B2 JP 7668273 B2 JP7668273 B2 JP 7668273B2 JP 2022522065 A JP2022522065 A JP 2022522065A JP 2022522065 A JP2022522065 A JP 2022522065A JP 7668273 B2 JP7668273 B2 JP 7668273B2
Authority
JP
Japan
Prior art keywords
difluoro
methyl
amino
cyclopropyl
oxazepino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022522065A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022551950A (ja
JP2022551950A5 (enExample
Inventor
ベレニー，ベンジャミン・リチャード
ブレナン，アルフィー
チェン，カイ・ミン・ジャック
デイヴィス，オーウェン・アレクサンダー
ハーンデン，アリス・クレア
ヘルダー，スウェン
ハックヴェール，ローズマリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Cancer Research Royal Cancer Hospital
Original Assignee
Institute of Cancer Research Royal Cancer Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Cancer Research Royal Cancer Hospital filed Critical Institute of Cancer Research Royal Cancer Hospital
Publication of JP2022551950A publication Critical patent/JP2022551950A/ja
Publication of JP2022551950A5 publication Critical patent/JP2022551950A5/ja
Application granted granted Critical
Publication of JP7668273B2 publication Critical patent/JP7668273B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
JP2022522065A 2019-10-14 2020-10-14 Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体 Active JP7668273B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201914860A GB201914860D0 (en) 2019-10-14 2019-10-14 Inhibitor compounds
GB1914860.0 2019-10-14
PCT/GB2020/052588 WO2021074620A1 (en) 2019-10-14 2020-10-14 [1,4]oxazepino[2,3-c]qui noli none derivatives as blc6 inhibitors

Publications (3)

Publication Number Publication Date
JP2022551950A JP2022551950A (ja) 2022-12-14
JP2022551950A5 JP2022551950A5 (enExample) 2023-10-19
JP7668273B2 true JP7668273B2 (ja) 2025-04-24

Family

ID=68619494

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022522065A Active JP7668273B2 (ja) 2019-10-14 2020-10-14 Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体

Country Status (13)

Country Link
US (1) US12528826B2 (enExample)
EP (1) EP4045510B1 (enExample)
JP (1) JP7668273B2 (enExample)
KR (1) KR20220083761A (enExample)
CN (1) CN114650995A (enExample)
AU (1) AU2020365518B2 (enExample)
CA (1) CA3157716A1 (enExample)
ES (1) ES3047908T3 (enExample)
GB (1) GB201914860D0 (enExample)
IL (1) IL292182B1 (enExample)
MX (1) MX2022004419A (enExample)
WO (1) WO2021074620A1 (enExample)
ZA (1) ZA202203520B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
CA3154386A1 (en) 2019-10-17 2021-04-22 Michael Berlin Bifunctional molecules containing an e3 ubiquitine ligase binding moiety linked to a bcl6 targeting moiety
KR20230171979A (ko) 2021-04-16 2023-12-21 아비나스 오퍼레이션스, 인코포레이티드 Bcl6 단백질 분해의 조절제 및 관련 사용 방법
PE20250756A1 (es) 2022-06-06 2025-03-13 Treeline Biosciences Inc Degradadores bifuncionales de bcl6 de quinolona triciclica
EP4536649A1 (en) 2022-06-13 2025-04-16 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
KR20250023481A (ko) 2022-06-13 2025-02-18 트리라인 바이오사이언시스, 인크. 1,8-나프티리딘-2-온 이종이작용성 bcl6 분해제
KR20240161027A (ko) * 2023-05-03 2024-11-12 인제대학교 산학협력단 BTK 분해제 및 Bcl-6 분해제를 포함하는 암의 예방 또는 치료용 약학적 조성물
AU2024331309A1 (en) * 2023-09-01 2026-03-19 Treeline Biosciences, Inc. Tricyclic quinolone bcl6 bifunctional degraders

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
JP2017536409A (ja) 2014-12-06 2017-12-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2018108704A1 (en) 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
WO2018215798A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0259572A (ja) 1988-08-23 1990-02-28 Mitsubishi Kasei Corp ベンズイミダゾロン誘導体又はその塩類
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CA2349616A1 (en) 1998-12-04 2000-06-15 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
IL147309A0 (en) 1999-07-21 2002-08-14 Fujisawa Pharmaceutical Co Benzimidazolone derivatives and pharmaceutical compositions containg the same
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
WO2001094311A1 (en) 2000-06-08 2001-12-13 Mitsubishi Pharma Corporation Cytoprotectors
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
UY27304A1 (es) 2001-05-24 2002-12-31 Avanir Pharmaceuticals Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
US20050256157A1 (en) 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
WO2008011032A1 (en) 2006-07-17 2008-01-24 Amgen Inc. Quinazoline and pyridopyrimidine derivatives as p38 kinase inhibitors
WO2008066887A2 (en) 2006-11-30 2008-06-05 Albert Einstein College Of Medicine Of Yeshiva University Small molecule inhibitors of bcl6
US8686008B2 (en) 2007-08-16 2014-04-01 The University Of Mississippi Highly selective sigma receptor ligands
WO2009063240A1 (en) 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
SG187502A1 (en) 2008-02-01 2013-02-28 Takeda Pharmaceutical Oxim derivatives as hsp90 inhibitors
AU2009314760B2 (en) 2008-11-11 2011-11-10 Je Il Pharmaceutical Co.,Ltd Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same
BRPI1006942A2 (pt) 2009-01-23 2016-04-12 Rigel Pharmaceuticals Inc composto, composição farmacêutica, kit, métodos para inibir uma atividade de uma jak quinase, para tratar uma doença, para tratar a rejeição de transplante de aloenxerto em um receptor de transplante, para tratar uma reação de hipersensibilidade, e para inibir uma cascata de transdução de sinal, e, uso do composto
KR20120114355A (ko) 2010-01-13 2012-10-16 글락소스미스클라인 엘엘씨 화합물 및 방법
CA2840883C (en) 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
EP2964642B1 (en) 2013-03-05 2017-11-15 F. Hoffmann-La Roche AG Inhibitors of bruton's tyrosine kinase
US9943506B2 (en) 2013-06-17 2018-04-17 Cornell University BCL6 inhibitors as anticancer agents
CN105017159B (zh) 2014-04-28 2019-05-17 四川大学 5-氟-2,4-二取代氨基嘧啶衍生物及其制备方法和用途
US10266549B2 (en) 2014-08-25 2019-04-23 Salk Institute For Biological Studies ULK1 inhibitors and methods using same
US20160060260A1 (en) 2014-08-29 2016-03-03 Board Of Regents, The University Of Texas System Bromodomain inhibitors for treating disease
WO2017007658A1 (en) 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
JP7202315B2 (ja) 2017-05-26 2023-01-11 キャンサー・リサーチ・テクノロジー・リミテッド ベンズイミダゾロン由来のｂｃｌ６阻害剤
CA3095371A1 (en) 2018-04-13 2019-10-17 Cancer Research Technology Limited Bcl6 inhibitors
GB201819136D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015526395A (ja) 2012-06-18 2015-09-10 ダート・ニューロサイエンス・（ケイマン）・リミテッド 置換ピリジンアゾロピリミジン−５−（６ｈ）−オン化合物
JP2017536409A (ja) 2014-12-06 2017-12-07 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2018108704A1 (en) 2016-12-13 2018-06-21 Boehringer Ingelheim International Gmbh New 6-amino-quinolinone compounds and derivatives as bcl6 inhibitors
WO2018215798A1 (en) 2017-05-26 2018-11-29 Cancer Research Technology Limited 2-quinolone derived inhibitors of bcl6

Also Published As

Publication number Publication date
AU2020365518B2 (en) 2026-04-23
JP2022551950A (ja) 2022-12-14
EP4045510A1 (en) 2022-08-24
IL292182A (en) 2022-06-01
KR20220083761A (ko) 2022-06-20
WO2021074620A1 (en) 2021-04-22
ZA202203520B (en) 2025-09-25
EP4045510C0 (en) 2025-07-30
WO2021074620A9 (en) 2021-06-17
MX2022004419A (es) 2022-08-08
US12528826B2 (en) 2026-01-20
CN114650995A (zh) 2022-06-21
GB201914860D0 (en) 2019-11-27
AU2020365518A1 (en) 2022-04-14
ES3047908T3 (en) 2025-12-05
EP4045510B1 (en) 2025-07-30
IL292182B1 (en) 2026-02-01
US20240217987A1 (en) 2024-07-04
CA3157716A1 (en) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7668273B2 (ja) Ｂｃｌ６阻害剤としての［１，４］オキサゼピノ［２，３－ｃ］キノリノン誘導体
US12486285B2 (en) BCL6 inhibitors
US11161839B2 (en) 2-quinolone derived inhibitors of BCL6
KR20190129936A (ko) Ｐｒｍｔ５-매개성 질환의 치료 또는 예방에 유용한 화합물
CN110621675A (zh) 用于治疗增殖性疾病的三环化合物
WO2020104820A1 (en) Substituted benzimidazolones as anti-cancer agents
US20230203029A1 (en) Naphthyridine compounds as inhibitors of mer tyrosine kinase and axl tyrosine kinase
US20240293392A1 (en) Inhibitor compounds
CN120858100A (zh) 抑制性化合物
HK40081687A (en) [1,4]oxazepino[2,3‑c]quinolinone derivatives as blc6 inhibitors
HK40081687B (en) [1,4]oxazepino[2,3‑c]quinolinone derivatives as blc6 inhibitors
EA047672B1 (ru) Производные [1,4]оксазепино[2,3-c]хинолинона в качестве ингибиторов bcl6
WO2025262192A1 (en) Quinazoline derivatives suitable for use as werner syndrome helicase protein inhibitors
JP2024543183A (ja) 阻害剤化合物
HK40046058A (en) Bcl6 inhibitors
HK40046058B (en) Bcl6 inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240905

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241203

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250318

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250414

R150 Certificate of patent or registration of utility model

Ref document number: 7668273

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150